I too am impressed with all the potential new applications and areas not even yet pursued. Molecules that can be manufactured to identify cancer cells, efficatious transfer and application of blood, bile, lymph....not just transfer or lack there of can be measured, but the rates of flows into and out of body organs and tissues. As an engineer I know how important this fine grained, targeted information is in identifying the "root cause" of system failures and inefficiencies. The possibility of micro surgery and even molecular level analysis opens treatments not even thought of today. The possibilities for Novadaq are comperable to those of Intuitive Surgicals. They are opening a new field. This is a new paradigm, a seminal point in medicine.
Don't miss this opportunity. They ussually only come once in a persons lifetime.
GSA
Sentiment: Strong Buy
If all you see is a LOSS, you are entirely missing the point. reread anderson's post. It mattters WHY they spent the money that resulted in this "LOSS" you are so infatuated with. If they were as infatuated with their short term results as you seem to be they could have forgine growing the company to eliminate the loss, but that would be a bad thing for the company and the shareHOLDERS. You clearly have no interest in investing in a company so you can't understand anything beyond short term factors that cause blips in the share price. Short of a general market collapse this will probably not see $10 again let alone $3
Ain't this guy a real pip? wow and so cleverly smart . we should real and follow his advice. those septic tank cleaners know their SH--,THAT'S FOR SURE
Sentiment: Strong Buy
If this message board is any indication, and I believe it is, there is very little retail interest in this stock. One reason is that the retail investor might be seeing the company as a one trick pony. On the other hand, as indicated by the institutional analyst questions today, Institutions are beginning to see this company in a very different light. Over and over today, in response to questions asked, the CEO indicated the inroads the company is making in expanding the types of operations where the use of its equipment is effective in reducing hosital costs through the reduction of post operative complications.
When you begin to aggregate the number of procedures in which the company's equipment can play a valuable role it is beginning to approach millions not thousands. And therein is why Andersongordon's statement about the stock still being a 10 bagger plus is not unreasonable. Two years from now it will be the razor blades driving profitabilty not new razors. Two years from now the use of this equipment as the standard of care in multiple procedures is very realistic. By the time the retail investor community realizes what is going on here, the pps is going to be out of their reach.
regards endo
The burn of ($1.7Million) can be attributed to the addition of 18 new marketing/sales persons for the PINPOINT and LUNA launches. They also added ~$1million in inventory for the same. If they hadn't "invested" for these new launches there would have been positive earnings of around $700k or ~$.02 per share! There is a self described 6-12 month lag between hiring and full production revenue out of the new sales force. There is also a lag of ~6 weeks from shipping of their new machines until the hospital has it installed, tested, training completed for surgeons and staff and actual ussage. This investment is absolutely prudent and GREAT news. It will add handsomely (1000%-5000%) to those long term stock holders.
They have $~37 Million cash on hand. At a burn rate of $1.7 Million per quarter, the revenue from these new ventures ($1.0 Million annual sales per person estimate from Q4 2012 CC) will kick in long before the cash runs out.
This could be one of those few companies that has the potential to exceed the 10 bagger status.
GSA
Sentiment: Strong Buy
anyway you look at it its a LOSS
First quarter of 2013 loss per share was $0.07. Excluding the impact of non-cash $2.1 million warrants revaluation expense in first quarter 2013, loss per share was $0.02, compared with $0.03 in first quarter 2012.
I'll buy all you have up to 40 million shares at $2.00. I'll even pay a premium above that.
GSA
There were so many good points made by the CEO during the CC that it is difficult to list them all. Needledd to say, they are currently operating on all 8 cylinders. Strongly suggest listening to the CC.
regards endo
Think again, thinker! I hope you haven't been short this stock - some people look in the rear view mirror and are blind to what is ahead of them?
Go ahead. Short it!! Put your money wherer your mouth is. Or are you scambling to cover this morning?
Novadaq Technologies (NASDAQ: NVDQ) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $6.94 million.
For earnings history and earnings-related data on Novadaq Technologies (NVDQ) click here.
stocks worth only $2
Sentiment: Strong Sell
great to see a company of this size and stage basically breakeven on cash flow. that means no more dilution.
Actual revenues $7.3M - EPS (excluding warrant revalution) of -$0.02. so just missed. 200 units of Spy Elite and Firefly shipped in Q1, with an increase of 130 on the installed - I think that is a record! Momentum is building - by this time next year, LUNA and PinPoint will be contributing to the exponential revenue and earnings growth - the next few years will be very interesting.
It is very difficult to estimate as there is no good source of direct or even indirect quatifiable indicators. ISRG reported 69 Firefly sales vs 88 Q4 and 64 Q3 2012. I estimate 45 vs 47 Q4 and 44 Q3 2012 SPY Elites from Life Cell. The unknown wild card are the PINPOINTs. 2 sold in Q4, I have 10 this quarter but that is based on speculative gut feelings only. They reported 10 sales and marketing people last quarter for PINPOINT and that they should be producing ~$1 million in revenue per year per person after 6-12 months. The question is how many early adopters or hospitals hearing of the preliminary/interim reports from the PILLAR study acted in Q1? I expect the cost side to ramp up faster than the revenues because of the 6-12 month lag, but the results are so compelling there may be some early adopters that want to have the competitive advantages of this new technology. Anachdotally I found a number of hospitals that were doing just this on their web sites. Warrants should have little impact this time as the closing price at Q4 and Q1 were about the same.
All contributions, remarks or other inputs are welcome.
Iron sharpens Iron. Proverbs 27:17
GSA
NVDQ on the Nasdaq has only been listed for a little over a year. Look at the chart for NDQ from the Toronto Stock Exchange over 5 years; no such pattern exists. Low of about 1.5 in 2009, followed by a nice classic growth pattern to current levels (with one exception, towards the end 2012, there was a spike from $8.5 to $11.5 and back again a month later).
Sentiment: Strong Buy
NVDQ worth only $3.25 not $13. Time for short again same as last year May. Every year May this stocks fall to new low.
Sentiment: Strong Sell
good news
strange

Analyst: Tumblr Fills Void in Yahoo's Offerings
Associated Press Videos - 2 hours 2 minutes ago
Forget Apple, Forget Google. This Stock Has Topped Them All
Talking Numbers - 2 hours 20 minutes ago